EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ceftazidime-Avibactam Regimens for the Treatment of Bacteremic and Non-Bacteremic Episodes of Carbapenemase-Producing Enterobacterales Infections in Immunosuppressed Patients

Fabián Herrera iD, Diego Torres iD, María Leone iD, Maximiliano Gabriel Castro iD, Jorge López Camelo, Elena Temporiti, Natalin Grippo, Silvia Relloso, Pablo Bonvehí

Pathogens · 2025

DOI: 10.3390/pathogens14121300 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathogens, 2025. Verfasst von Fabián Herrera und 8 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Section, Internal Medicine Department, Centro de Educación Médica e Investigaciones Clínicas, CEMIC, Buenos Aires C1431, Argentin…. Hauptthemen laut MEDLINE: Ceftazidime, Bacteremia, Azabicyclo Compounds, Enterobacteriaceae Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ceftazidime-avibactam (CA) and CA plus aztreonam (ATM) are the preferred treatment options for KPC and MBL carbapenemase-producing Enterobacterales infections (CPEis). All episodes of monomicrobial CPEis in immunosuppressed patients (IPs) admitted from May 2019 to November 2024, who received definitive antibiotic therapy (AT) with CA or CA + ATM for at least 72 h, were prospectively included. Bacteremic episodes (BEs) and non-bacteremic episodes (NBEs) were compared. Logistic regressions adjusted by propensity score were used to identify variables associated with 30-day overall mortality. In total, 82 CPEis were included (38 NBEs and 44 BEs). BEs more frequently occurred in hematological malignancies (52.3% vs. 15.8%, p = 0.0006), while NBEs were more commonly observed in solid organ transplantation (73.7% vs. 34.1%, p = 0.001). K. pneumoniae was the main isolated microorganism; KPC-CPE was the most common resistance mechanism in both groups, followed by MBL-CPE. The 7-day clinical response, 30-day overall and infection-related mortality between NBEs and BEs were 92.1% vs. 88.6%, p = 0.59, 10.5% vs. 27.3%, p = 0.09, and 2.6% vs. 13.6%, p = 0.11. Septic shock, OR 6.5, 95% CI, 1.58–26.72 (p = 0.01), and refractory malignancy, OR 5.6, 95% CI, 1.03–30.14 (p = 0.046), were associated with 30-day mortality, whereas BEs were not, OR 1.5, 95% CI, 0.36–6.2 (p = 0.56). CPEis in both NBE and BE IPs who received definitive AT with CA or CA + ATM correlated with a high rate of 7-day clinical response and low 30-day infection-related mortality. Underlying malignancy and disease severity were associated with 30-day overall mortality. Regional knowledge of bacterial antibiotic resistance enables the implementation of individualized AT to improve patient survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeftazidimeBacteremiaAzabicyclo CompoundsEnterobacteriaceae InfectionsAnti-Bacterial AgentsImmunocompromised HostCarbapenem-Resistant EnterobacteriaceaeHumansMaleFemaleMiddle AgedDrug CombinationsAgedbeta-LactamasesProspective StudiesBacterial ProteinsAdult

Stichwörter der Autor:innen

carbapenemase-producing enterobacteralesceftazidime-avibactamimmunosuppressed patients

Substanzen

Ceftazidimeavibactam, ceftazidime drug combinationAzabicyclo CompoundsDrug CombinationsAnti-Bacterial Agentsbeta-LactamasescarbapenemaseBacterial Proteins

Autor:innen und Institutionen

  • Infectious Diseases Section, Internal Medicine Department, Centro de Educación Médica e Investigaciones Clínicas, CEMIC, Buenos Aires C1431, Argentina.
  • CEMIC-CONICET Research Unit, Centro de Educación Médica e Investigaciones Clínicas, CEMIC, Buenos Aires C1431, Argentina.
  • Microbiology Laboratory, Centro de Educación Médica e Investigaciones Clínicas, CEMIC, Buenos Aires C1431, Argentina.

ORCID-Profile: Fabián Herrera, Diego Torres, María Leone, Maximiliano Gabriel Castro

Zitieren

APA

Herrera, F., Torres, D., Leone, M., Castro, M. G., Camelo, J. L., Temporiti, E., Grippo, N., Relloso, S., & Bonvehí, P. (2025). Ceftazidime-Avibactam Regimens for the Treatment of Bacteremic and Non-Bacteremic Episodes of Carbapenemase-Producing Enterobacterales Infections in Immunosuppressed Patients. Pathogens. https://doi.org/10.3390/pathogens14121300

Vancouver

Herrera F, Torres D, Leone M, Castro MG, Camelo JL, Temporiti E, et al. Ceftazidime-Avibactam Regimens for the Treatment of Bacteremic and Non-Bacteremic Episodes of Carbapenemase-Producing Enterobacterales Infections in Immunosuppressed Patients. Pathogens. 2025. doi:10.3390/pathogens14121300

BibTeX
@article{Herrera2025,
  author = {Herrera, Fabián and Torres, Diego and Leone, María and Castro, Maximiliano Gabriel and Camelo, Jorge López and Temporiti, Elena and Grippo, Natalin and Relloso, Silvia and Bonvehí, Pablo},
  title = {Ceftazidime-Avibactam Regimens for the Treatment of Bacteremic and Non-Bacteremic Episodes of Carbapenemase-Producing Enterobacterales Infections in Immunosuppressed Patients},
  journal = {Pathogens},
  year = {2025},
  doi = {10.3390/pathogens14121300}
}
Kostenlos starten →